Kasra Javadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kasra Javadi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Abazar Pournajaf
Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
2 shared publications Arghavan Zebardast
Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
2 shared publicationsAkbar Dorgalaleh
1 shared publicationAmirhossein Rajabnia
Department of Endodontics, School of Dentistry, Golestan University of Medical Sciences, Gorgan, Iran
1 shared publicationDelaram Abedi Firouzjaei
Department of Pediatric Dentistry, School of Dentistry, Golestan university of Medical Sciences, Gorgan, Iran
1 shared publicationEzatolah Kazeminejad
Department of Endodontics, School of Dentistry, Golestan University of Medical Sciences, Gorgan, Iran; Dental Research Center, Golestan University of Medical Sciences, Gorgan, Iran
1 shared publication
Latest Publications
- 24 August 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 220
The coagulation system and bacterial infections: A double-edged sword of host defense and pathogen evasion
- 24 August 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 220
The coagulation system and bacterial infections: A double-edged sword of host defense and pathogen evasion
- Open Access
- 18 June 2026
- Published by Springer Nature in Gut Pathogens
- Vol. 18 (1)
Human microbiome alterations in Epstein–Barr Virus infection: a systematic review
Epstein-Barr virus (EBV) is associated with several malignancies and immune-mediated conditions, but its relationship with human microbial communities remains incompletely understood. We systematically searched PubMed, Embase, and Scopus for human studies evaluating EBV-associated alterations in the microbiome. Because of substantial clinical and methodological heterogeneity, findings were synthesized narratively, and study quality was assessed using the ROBINS-I tool. Nine observational studies published between 2017 and 2025 were included, covering the oral cavity, nasopharynx, gut, gastric tissue, and subgingival plaque. EBV positivity or EBV-related clinical status was associated with niche-specific microbial shifts, including altered gut bacterial profiles, distinct microbial patterns in EBV-associated gastric cancer tissue, and enrichment of oral-associated pathobionts in nasopharyngeal carcinoma compartments. Alpha- and beta-diversity findings were inconsistent across studies. Overall, the evidence suggests context-dependent alterations in the microbiome in EBV-positive or EBV-related disease settings. However, these findings should be interpreted as EBV-associated rather than EBV-specific, particularly when EBV status overlaps with malignancy. The small observational evidence base, heterogeneous EBV-status definitions, methodological variability, and residual confounding limit causal inference. Larger longitudinal and standardized multi-omic studies are needed to clarify directionality, mechanisms, and clinical relevance.
- 18 June 2026
- Published by Springer Nature in Gut Pathogens
- Vol. 18 (1)
Open AccessHuman microbiome alterations in Epstein–Barr Virus infection: a systematic review
Epstein-Barr virus (EBV) is associated with several malignancies and immune-mediated conditions, but its relationship with human microbial communities remains incompletely understood. We systematically searched PubMed, Embase, and Scopus for human studies evaluating EBV-associated alterations in the microbiome. Because of substantial clinical and methodological heterogeneity, findings were synthesized narratively, and study quality was assessed using the ROBINS-I tool. Nine observational studies published between 2017 and 2025 were included, covering the oral cavity, nasopharynx, gut, gastric tissue, and subgingival plaque. EBV positivity or EBV-related clinical status was associated with niche-specific microbial shifts, including altered gut bacterial profiles, distinct microbial patterns in EBV-associated gastric cancer tissue, and enrichment of oral-associated pathobionts in nasopharyngeal carcinoma compartments. Alpha- and beta-diversity findings were inconsistent across studies. Overall, the evidence suggests context-dependent alterations in the microbiome in EBV-positive or EBV-related disease settings. However, these findings should be interpreted as EBV-associated rather than EBV-specific, particularly when EBV status overlaps with malignancy. The small observational evidence base, heterogeneous EBV-status definitions, methodological variability, and residual confounding limit causal inference. Larger longitudinal and standardized multi-omic studies are needed to clarify directionality, mechanisms, and clinical relevance.
- 21 May 2026
- Published by Springer Nature in Folia Microbiologica
The role of liquid biopsy in the molecular characterization of HPV-related cancers
Human papillomavirus (HPV)-related cancers represent a significant and growing global health burden, encompassing cervical, anogenital, and an increasing proportion of head and neck squamous cell carcinomas, particularly oropharyngeal cancer. While tissue biopsy remains the cornerstone of diagnosis and initial molecular characterization, its invasive nature and inability to capture tumor heterogeneity or dynamic molecular changes limit its utility for longitudinal disease monitoring. Liquid biopsy has emerged as a powerful, minimally invasive approach that enables real-time assessment of tumor- and virus-derived biomarkers from blood, saliva, and other body fluids. Among these, circulating tumor HPV DNA (ctHPV-DNA) has demonstrated exceptional specificity and sensitivity, in HPV-driven malignancies, where viral DNA serves as a highly tumor-specific marker. Advances in analytical platforms, including droplet digital PCR and next-generation sequencing, have markedly improved the detection of low-abundance circulating biomarkers, enabling applications ranging from early detection and treatment response monitoring to minimal residual disease assessment and early identification of recurrence. This review provides a comprehensive overview of the current landscape of liquid biopsy in HPV-related cancers.
- 21 May 2026
- Published by Springer Nature in Folia Microbiologica
The role of liquid biopsy in the molecular characterization of HPV-related cancers
Human papillomavirus (HPV)-related cancers represent a significant and growing global health burden, encompassing cervical, anogenital, and an increasing proportion of head and neck squamous cell carcinomas, particularly oropharyngeal cancer. While tissue biopsy remains the cornerstone of diagnosis and initial molecular characterization, its invasive nature and inability to capture tumor heterogeneity or dynamic molecular changes limit its utility for longitudinal disease monitoring. Liquid biopsy has emerged as a powerful, minimally invasive approach that enables real-time assessment of tumor- and virus-derived biomarkers from blood, saliva, and other body fluids. Among these, circulating tumor HPV DNA (ctHPV-DNA) has demonstrated exceptional specificity and sensitivity, in HPV-driven malignancies, where viral DNA serves as a highly tumor-specific marker. Advances in analytical platforms, including droplet digital PCR and next-generation sequencing, have markedly improved the detection of low-abundance circulating biomarkers, enabling applications ranging from early detection and treatment response monitoring to minimal residual disease assessment and early identification of recurrence. This review provides a comprehensive overview of the current landscape of liquid biopsy in HPV-related cancers.
- 1 April 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105314
Microbiota and esophageal cancer: From dysbiosis to carcinogenesis
- 1 April 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105314
Microbiota and esophageal cancer: From dysbiosis to carcinogenesis
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Microbiology
- Vol. 2025 (1) , 1009049
Investigating the Link Between Biofilm Formation and Antibiotic Resistance in Clinical Isolates of Acinetobacter baumannii
Background: Acinetobacter baumannii has become a significant problem in hospitals worldwide during the last decades. Biofilm formation is a virulence factor that may affect antibiotic resistance. This study aimed to elucidate the correlation between biofilm formation and biofilm‐related and oxacillinase genes in A . baumannii clinical isolates. Methods: This study was conducted on 53 A . baumannii isolates collected from hospitals affiliated with Babol University of Medical Sciences (Babol, Iran) from April to October 2023. Kirby–Bauer disc diffusion was used to determine antibacterial resistance. Biofilm formation was examined using crystal violet staining. Polymerase chain reaction was used to detect oxacillinase ( b l a OXA−23 , b l a OXA−24 , b l a OXA−51 , and b l a OXA−58 ) and biofilm‐encoding ( bap and b l a PER−1 ) genes using specific primers. Results: The strains showed the highest resistance to trimethoprim/sulfamethoxazole and ciprofloxacin (98.11%) and the lowest resistance to ampicillin/sulbactam (66.03%). All isolates formed biofilms. Also, 67.92%, 18.86%, and 11.32% were strong, moderate, and weak biofilm producers, respectively. The frequencies of b l a OXA−23 , b l a OXA−24 , b l a OXA−51 , bap , and b l a PER−1 genes were 92.45%, 71.69%, 100%, 73.58%, and 58.49%, respectively. None of the isolates harbored b l a OXA−58 . Conclusions: A high prevalence of antibiotic‐resistant strains was found among A . baumannii clinical isolates. There was no significant correlation between the clinical sample type and biofilm formation, but a notable link was found between antimicrobial resistance and biofilm formation, except for ciprofloxacin. Oxacillinase genes were not significantly correlated with biofilm formation, but biofilm production was associated with bap rather than b l a PER−1 . Understanding the A . baumannii biofilm formation process is crucial for effective control of associated infections by targeting this mechanism.
- 1 January 2025
- Published by Wiley in International Journal of Microbiology
- Vol. 2025 (1) , 1009049
Open AccessInvestigating the Link Between Biofilm Formation and Antibiotic Resistance in Clinical Isolates of Acinetobacter baumannii
Background: Acinetobacter baumannii has become a significant problem in hospitals worldwide during the last decades. Biofilm formation is a virulence factor that may affect antibiotic resistance. This study aimed to elucidate the correlation between biofilm formation and biofilm‐related and oxacillinase genes in A . baumannii clinical isolates. Methods: This study was conducted on 53 A . baumannii isolates collected from hospitals affiliated with Babol University of Medical Sciences (Babol, Iran) from April to October 2023. Kirby–Bauer disc diffusion was used to determine antibacterial resistance. Biofilm formation was examined using crystal violet staining. Polymerase chain reaction was used to detect oxacillinase ( b l a OXA−23 , b l a OXA−24 , b l a OXA−51 , and b l a OXA−58 ) and biofilm‐encoding ( bap and b l a PER−1 ) genes using specific primers. Results: The strains showed the highest resistance to trimethoprim/sulfamethoxazole and ciprofloxacin (98.11%) and the lowest resistance to ampicillin/sulbactam (66.03%). All isolates formed biofilms. Also, 67.92%, 18.86%, and 11.32% were strong, moderate, and weak biofilm producers, respectively. The frequencies of b l a OXA−23 , b l a OXA−24 , b l a OXA−51 , bap , and b l a PER−1 genes were 92.45%, 71.69%, 100%, 73.58%, and 58.49%, respectively. None of the isolates harbored b l a OXA−58 . Conclusions: A high prevalence of antibiotic‐resistant strains was found among A . baumannii clinical isolates. There was no significant correlation between the clinical sample type and biofilm formation, but a notable link was found between antimicrobial resistance and biofilm formation, except for ciprofloxacin. Oxacillinase genes were not significantly correlated with biofilm formation, but biofilm production was associated with bap rather than b l a PER−1 . Understanding the A . baumannii biofilm formation process is crucial for effective control of associated infections by targeting this mechanism.
- Open Access
- 30 September 2024
- Published by Maad Rayan Publishing Company in Avicenna Journal of Clinical Microbiology and Infection
- Vol. 11 (3) , 141-146
Acinetobacter baumannii in the Healthcare Facility Setting
Acinetobacter baumannii is a significant cause of healthcare-associated infections, particularly in intensive care units, where its ability to develop multidrug resistance complicates treatment and control efforts. This review highlights the bacteriology, ecology, virulence mechanisms, and antibiotic resistance strategies of A. baumannii, with an emphasis on its clinical impact in healthcare settings. The pathogen’s resistance is fueled by genetic mutations, enzyme production, and efflux pumps, leading to resistance against carbapenems and other key antibiotics. It can cause infections in various body sites, including the lungs, bloodstream, and urinary tract, and has a high mortality rate, especially in vulnerable patients. A. baumannii’s ability to survive on dry surfaces for extended periods contributes to its spread within healthcare facilities, exacerbating outbreak risks. Effective prevention strategies, such as strict infection control protocols, environmental cleaning, and antibiotic stewardship, are essential for minimizing the pathogen’s impact. Continued research into new antibiotics and treatment approaches is critical to managing this formidable public health threat.
- 30 September 2024
- Published by Maad Rayan Publishing Company in Avicenna Journal of Clinical Microbiology and Infection
- Vol. 11 (3) , 141-146
Open AccessAcinetobacter baumannii in the Healthcare Facility Setting
Acinetobacter baumannii is a significant cause of healthcare-associated infections, particularly in intensive care units, where its ability to develop multidrug resistance complicates treatment and control efforts. This review highlights the bacteriology, ecology, virulence mechanisms, and antibiotic resistance strategies of A. baumannii, with an emphasis on its clinical impact in healthcare settings. The pathogen’s resistance is fueled by genetic mutations, enzyme production, and efflux pumps, leading to resistance against carbapenems and other key antibiotics. It can cause infections in various body sites, including the lungs, bloodstream, and urinary tract, and has a high mortality rate, especially in vulnerable patients. A. baumannii’s ability to survive on dry surfaces for extended periods contributes to its spread within healthcare facilities, exacerbating outbreak risks. Effective prevention strategies, such as strict infection control protocols, environmental cleaning, and antibiotic stewardship, are essential for minimizing the pathogen’s impact. Continued research into new antibiotics and treatment approaches is critical to managing this formidable public health threat.